Disruptive APDS technology for the treatment of dysglycaemia

Brittle diabetes is a special form that affects one in three out of every 1,000 insulin-dependent patients. Recurrent episodes of DKA and the resulting hospitalisation reduce the quality of life of these people enormously. Conventional diabetes treatments often do not achieve the desired results. A new innovative approach with a disruptive technology now promises to optimise the regulation of blood glucose levels and increase the time-in-range, which should improve the course of the disease and the quality of life of those affected and reduce constant hospital stays. See for yourself!